



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/614,922	07/08/2003	Yoichi Mikami	10793-007-999	9246

20583 7590 03/02/2006

JONES DAY
222 EAST 41ST ST
NEW YORK, NY 10017

EXAMINER

MARX, IRENE

ART UNIT PAPER NUMBER

1651

DATE MAILED: 03/02/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

DETAILED ACTION

The application should be reviewed for errors.

To facilitate processing of papers at the U.S. Patent and Trademark Office, it is recommended that the Application Serial Number be inserted on every page of claims and/or of amendments filed.

The status of the parent case(s) should be updated.

Strain *B. stearoothermophilus* JTS 859 has been deposited at National Institute of Biosciences and Human Technology of the Agency of Industrial Science and Technology under accession number FERM-BP- 6885 (Specification page 12). The deposit requirements are met in application serial No. 09/808448, now U.S. Patent No. 6,620,596(MPEP 2404.01).

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 2-5 and 7-10 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 2 is vague and indefinite in the recitation of "as purine nucleoside phosphorylase and pyrimidine nucleoside phosphorylase, a microorganism itself which contains said enzymes or said enzymes derived from the microorganism are used". Amendment to --wherein the microbial purine nucleoside phosphorylase and pyrimidine nucleoside phosphorylase are contained in a microorganism or are obtained from a microorganism--, would be remedial, provided that claim 1 is amended to recite "microbial purine nucleoside phosphorylase and pyrimidine nucleoside phosphorylase".

Claims 4 and 5 are substantial duplicates.

Claims 1 and 6 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for the claimed biotransformation with a microbial purine nucleoside phosphorylase and pyrimidine nucleoside phosphorylase, does not reasonably provide

Art Unit: 1651

enablement for the use of enzymes from other sources. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

The factors to be considered in determining whether undue experimentation is required are summarized in *In re Wands*, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988) (a) the breadth of the claims; (b) the nature of the invention; (c) the state of the prior art; (d) the level of one of ordinary skill; (e) the level of predictability in the art; (f) the amount of direction provided by the inventor; (g) the existence of working examples; and (h) the quantity of experimentation needed to make or use the invention based on the content of the disclosure. While all of these factors are considered, a sufficient number are discussed below so as to create a *prima facie* case.

The breadth of the claims reads on a biotransformation procedure that can use an enzyme from any origin. Use of enzymes requires knowledge of a process for preparing them, knowledge of working conditions under which the enzyme retains activity and provision of any co-factors required by the enzymatic reaction in question. Thus, the conditions required for preparation and activity of a previously unknown enzyme are not *a priori* predictable. As set forth in *Ex parte Jackson*, 217 U.S.P.Q. 804 (Bd. App. 1982)., the determination of what constitutes undue experimentation in a given case requires the application of a standard of reasonableness, having due regard for the nature of the invention and the state of the art. The test is not merely quantitative, since a considerable amount of experimentation is permissible if it is merely routine or if the specification in question provides a reasonable amount of guidance with respect to the direction in which the experimentation should proceed to enable the determination of how to practice a desired embodiment of the invention claimed. Here, applicants' specification provides no guidance with respect to the selection or preparation of enzymes from a source other than a microorganism which would effect the claimed reaction. Moreover, Applicants rely on no reference indicating the state of the art with respect to this issue.

Accordingly, undue experimentation would be required to practice the claimed invention with respect to the selection and preparation of enzymes derived from sources other than microorganisms, particularly since a specific selection procedure, not described in the specification, would be required to avoid undue experimentation.

Art Unit: 1651

Thus, sound technical reasoning has been provided to support the conclusion that the limited guidance in the specification, considered in light of the relatively high degree of unpredictability in the particular art in question, would not have enabled one having ordinary skill in the art to practice the broad scope of the claimed invention without undue experimentation. In re Fischer 166 USPQ 18 (CCPA 1970)ydrolases would work in this instance.


Thus, the scope of the claims is not commensurate with the teachings of enablement of the specification.

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Irene Marx whose telephone number is (571) 272-0919. The examiner can normally be reached on M-F (6:30-3:00).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Wityshyn can be reached on 571-272-0926. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300 .

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


Irene Marx
Primary Examiner
Art Unit 1651